Cormedix (19KA) Financial Statements
Cormedix Financial Overview
Cormedix's market cap is currently $396.13M. The company's EPS TTM is $2.41; its P/E ratio is 2.36; Cormedix is scheduled to report earnings on November 11, 2026, and the estimated EPS forecast is $-0.09. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 311.71M | $ 43.47M | $ 0.00 | $ 65.41K | $ 190.94K |
| Gross Profit | $ 275.75M | $ 40.28M | $ -205.56K | $ 61.67K | $ 42.00K |
| Operating Income | $ 150.14M | $ -22.36M | $ -48.96M | $ -30.62M | $ -29.44M |
| EBITDA | $ 167.35M | $ -18.98M | $ -46.23M | $ -30.18M | $ -29.38M |
| Net Income | $ 163.06M | $ -17.93M | $ -46.34M | $ -29.70M | $ -28.21M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 149.52M | $ 51.69M | $ 76.03M | $ 59.02M | $ 65.47M |
| Total Assets | $ 826.14M | $ 118.85M | $ 82.06M | $ 62.04M | $ 68.95M |
| Total Debt | $ 148.91M | $ 517.01K | $ 667.63K | $ 802.43K | $ 923.80K |
| Net Debt | $ 3.09M | $ -40.13M | $ -42.98M | $ -42.57M | $ -52.39M |
| Total Liabilities | $ 420.83M | $ 34.19M | $ 11.92M | $ 6.98M | $ 6.15M |
| Stockholders' Equity | $ 405.31M | $ 84.66M | $ 70.14M | $ 55.06M | $ 62.80M |
| Cash Flow | |||||
| Free Cash Flow | $ 172.79M | $ -50.73M | $ -38.74M | $ -24.58M | $ -22.58M |
| Operating Cash Flow | $ 175.05M | $ -50.62M | $ -38.41M | $ -24.36M | $ -21.16M |
| Investing Cash Flow | $ -308.43M | $ 21.23M | $ -17.06M | $ -3.71M | $ -9.13M |
| Financing Cash Flow | $ 238.45M | $ 26.32M | $ 55.92M | $ 17.90M | $ 41.76M |
Currency in USD